# A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis

> **NCT01565655** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 289 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** peficitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01565655
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-19
- **Primary completion:** 2013-12-02
- **Final completion:** 2013-12-02
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01565655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01565655, "A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01565655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*